NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading GH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown some recent momentum and aims for significant revenue growth in the coming year.
The market appears to have priced in a justified valuation, with low fragility and a premium compared to peers. However, there is a notable expectations gap, indicating that the market may not fully believe in the company's ability to meet its ambitious targets.
Management is on track to achieve its revenue growth target of 32% to 34% for 2026, although gross margins and cash flow burn are mixed. Recent financial performance has been weak, and while the miss probability is low, there is a history of earnings surprises trending down.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX, which could either support GH's growth or signal a fading tailwind. Additionally, any reversal in guidance from GH could severely impact credibility and market perception.
In the next 1 to 3 years, GH's performance will depend on both internal execution and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this growth target shows Guardant Health is on track for its annual goals. It confirms strong demand for its oncology and screening products.
Confirms:Q2 revenue growth of 32% or more compared to Q2 2025.
Disproves:Q2 revenue growth falls below 30% compared to Q2 2025.
Why it matters: The earnings report will show if the company can improve its financial performance. Investors will look for signs of recovery.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue decline or flat growth year over year.
Why it matters: A new CMO could impact strategy and operations. This is important after the recent departure.
Confirms one read:A new Chief Medical Officer was announced. This person has the right experience.
Confirms the other:No appointment is made within the next three months, causing uncertainty.
Why it matters: The CMO leaving might change product plans and how they are carried out. This creates uncertainty.
Confirms:No bad changes in operations have been reported since the CMO left.
Disproves:There have been reports of problems or changes in strategy after the CMO left.
Why it matters: This change may affect the company's plans and actions. It could change how investors feel.
Confirms:Good news about new leaders or plans after the departure.
Disproves:Negative news or setbacks related to the CMO's departure.
Why it matters: This revenue shows that many people are using the Shield screening tests. It shows good marketing and partnerships.
Confirms:Screening revenue of $186 million or more for 2026.
Disproves:Screening revenue falls below $162 million for 2026.
Why it matters: This margin shows that Guardant Health is keeping costs low while making more money. This is important for staying strong in the long run.
Confirms:Non-GAAP gross margin above 64% for 2026.
Disproves:Non-GAAP gross margin falls below 64% for 2026.
Why it matters: Cutting cash burn is important for financial health. It shows better cost control and efficiency.
Confirms:Free cash flow burn of $185 million or less for 2026.
Disproves:Free cash flow burn exceeds $195 million for 2026.
